HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

Clinical trial NCT07647432 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07647432
Sponsor: University of Illinois at Chicago
Status: NOT_YET_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Plasmablastic Lymphoma Hiv Consolidation

Start date: 2026-12-01
Primary completion: 2029-12-01
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.